This is of interest as AURKA is the target for alisertib (MLN8237), which was recently demonstrated to promote megakaryocyte polyploidization and ameliorate the myelofibrosis phenotype in mouse models (Wen et al., 2015), with some efficacy also in patients with myelofibrosis (Gangat et al., 2019). Here, AURKA is linked to myelofibrosis.